IL1B and systemic-onset juvenile idiopathic arthritis: Canakinumab or ILARIS®, a human monoclonal antibody targeted specifically at IL-1β, is approved for the treatment of autoinflammatory conditions such as Periodic Fever Syndromes (e.g., Cryopyrin-Associated Periodic Syndromes, Tumor Necrosis Factor Receptor Associated Periodic Syndrome, Familial Mediterranean Fever) and Systemic Juvenile Idiopathic Arthritis [22–23].